Uploaded October 2023 | Updated November 2026, 1 day ago
Nancy Moran, Ph.D., is the Raymer Chair and professor of integrative biology at the University of Texas at Austin. She earned her B.A. from the University of Texas at Austin in biology in 1976, and then moved to the University of Michigan to earn her Ph.D. in zoology in 1982. She has served on the faculty at the University of Arizona (1986-2010), Yale University (2010-2013) and UT Austin (2013-present). Moran’s research has long focused on symbiotic bacteria that live in insects, especially on their evolutionary histories, genomics and biological functions in hosts. Her recent research projects have involved symbiosis in beneficial pollinators including honey bees and bumble bees, and on plant pests, including aphids and leafhoppers. She has mentored many graduate students and postdoctoral researchers. Most have gone on to start their own research groups, mostly as academic faculty, and mostly working on insect symbiosis and related topics. Moran is a member of the National Academy of Science, fellow of the American Academy of Arts and Sciences and fellow of the American Academy of Microbiology. Her awards include a John D. and Catherine T. MacArthur Award, the International Prize in Biology, the Jim Tiedje award from the International Society for Microbial Ecology and the Lifetime Contribution award from the Society for Molecular Biology and Evolution.
Nancy Moran, Ph.D., is the Raymer Chair and professor of integrative biology at the University of Texas at Austin. She earned her B.A. from the University of Texas at Austin in biology in 1976, and then moved to the University of Michigan to earn her Ph.D. in zoology in 1982. She has served on the faculty at the University of Arizona (1986-2010), Yale University (2010-2013) and UT Austin (2013-present). Moran’s research has long focused on symbiotic bacteria that live in insects, especially on their evolutionary histories, genomics and biological functions in hosts. Her recent research projects have involved symbiosis in beneficial pollinators including honey bees and bumble bees, and on plant pests, including aphids and leafhoppers. She has mentored many graduate students and postdoctoral researchers. Most have gone on to start their own research groups, mostly as academic faculty, and mostly working on insect symbiosis and related topics. Moran is a member of the National Academy of Science, fellow of the American Academy of Arts and Sciences and fellow of the American Academy of Microbiology. Her awards include a John D. and Catherine T. MacArthur Award, the International Prize in Biology, the Jim Tiedje award from the International Society for Microbial Ecology and the Lifetime Contribution award from the Society for Molecular Biology and Evolution.


![Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme
Air date: Wednesday, February 1, 2023, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture [WALS]
See https://en.wikipedia.org/wiki/Helen_Blau
For more information go to https://oir.nih.gov/wals
Author: Helen Blau, Ph.D., Stanford Medicine
Permanent link: https://videocast.nih.gov/watch=46058 Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme](https://i.ytimg.com/vi/rPVoQesTplU/mqdefault.jpg)


![Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras
Air date: Wednesday, March 8, 2023, 2PM
Description: NIH Directors WALS Lecture [WALS]
Kevan Shokat is a chemist who discovers drugs against some of the most common drivers of human cancers. He is best known for targeting a mutation that drives more than 1 in 10 lung cancers, opening up a new arena of cancer treatment discovery. The target, K-Ras, is the most common driver of cancer, and was considered “undruggable” by most cancer researchers after 40 years of failed attempts to block its function. Dr. Shokat’s discovery of a K-Ras blocker broke through this decades-old barrier and threw open the doors to a new class of cancer treatments. Lecture summary: 1. To understand the chemical, biochemical and cellular challenges to identifying a drug to target K-Ras mutant tumors 2. To learn how to discover drugs which only target oncogenes in cancer cells while sparing signaling in the rest of the body using covalent chemistry. 3. To learn about new approaches for combination therapy in cancer including re-activation of the tumor suppressor p53 and engaging the immune cells to overcome resistance to targeted therapies.
https://cancer.ucsf.edu/people/shokat.kevan
For more information go to https://oir.nih.gov/wals
Author: Kevan Shokat, Ph.D., University of California, Berkeley
Permanent link: https://videocast.nih.gov/watch=46070 Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras](https://i.ytimg.com/vi/rtR3yl5U4yk/mqdefault.jpg)




